[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-impairments\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-impairments":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,47,72,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100641976","tis-for-improving-cognitive-impairment-in-schizophrenia-100641976",false,"NCT07647380","TIS for Improving Cognitive Impairment in Schizophrenia","Efficacy and Safety of Time Interference Stimulation on Cognitive Impairment in Patients With Schizophrenia","Inclusion Criteria:\n\n* Age 18-50 years old;\n* meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) diagnostic criteria;\n* the diagnosis of schizophrenia is confirmed by the Structured Clinical Interview for DSM-5 (SCID-5);\n* the disease duration does not exceed 8 years;\n* 1-2 antipsychotic drugs are taken, and the treatment dose of antipsychotic drugs was stable for at least 1 week before enrollment. Mood stabilizers, antidepressants, and excessive benzodiazepines (lorazepam when 2 doses exceeded 2 mg\u002Fd) are not allowed;\n* The type of antipsychotic drugs remains unchanged during treatment, and the dose is adjusted by no more than 25%;\n* Impaired functioning in daily activities;\n* The Global Deficit Score (GDS) for the MATRICS Consensus Cognitive Battery (MCCB) reaches 0.5 or above;\n* Agree to participate in this study and provide written informed consent\n\nExclusion Criteria:\n\n* Presence of other psychiatric comorbidities, intellectual disability, obvious mood symptoms, or substance use disorders (other than caffeine and\u002For tobacco);\n* with clear drug-induced extrapyramidal reaction;\n* A history of seizures, meningitis, or encephalitis;\n* with contraindications to transcranial electrical stimulation;\n* History of intracranial tumors or surgery;\n* history of severe head trauma;\n* have received other regimens of electrical or magnetic therapy in 1 month before enrollment.","ALL","18 Years","50 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to evaluate the efficacy, safety, and underlying neural mechanisms of TIS targeting the hippocampus in ameliorating cognitive impairment associated with schizophrenia (CIAS). Researchers will compare active TIS to a sham control to see if TIS works to treat CIAS. Participants will receive TIS twice a day for 2 weeks. Their clinical data, including the baseline clinical symptom scale score, cognitive function, E\u002FI imbalance index recorded by EEG, and MRI data, will be collected at baseline, at the end of the 2-week intervention, and 4 weeks after the intervention.",[27,28],"Schizophrenia Disorder","Cognitive Impairments",[30,31,32,33],"schizophrenia","cognitive impairments","temporal interference stimulation","excitatory-inhibitory imbalance","NOT_YET_RECRUITING","2026-06-09",{"date":37,"type":38},"2026-06-15","ACTUAL",{"date":40,"type":21},"2026-05-30",{"date":42,"type":21},"2026-12-30",{"name":44,"class":45},"Central South University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100508114","cognitive-training-for-cancer-related-cognitive-impairment-in-breast-cancer-survivors-100508114","NCT05896189","Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors","Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial","Inclusion Criteria:\n\n* The participant must provide study-specific informed consent prior to any study specific procedures and authorization permitting release of personal health information.\n* The participant must have a first time diagnosis of non-metastatic breast cancer which is Stage I-III.\n* The participant must have a score of less than 12 on the PROMIS Adult v2.0 - Cognitive Function 4a.\n* Participants must be at least 6 months and no more than 5 years (after completion of initial surgery +\u002F- adjuvant chemotherapy\u002Fradiation therapy) and targeted therapies (e.g., PARP inhibitors, CDK4\u002F6, or immunotherapy). Participants may still be taking endocrine therapy and\u002For trastuzumab.\n* The participant must be able to understand, speak, read, and write in English or Spanish.\n\nExclusion Criteria:\n\n* Scoring less than or equal to 3 on the 6-item cognitive screen.\n* Patient Health Questionnaire-2 item (PHQ-2) score of greater than or equal to 3.\n* Definitive clinical or radiologic evidence of metastatic disease.\n* Current or past history of another cancer. Patients with history of only non-melanoma skin cancer or in situ cervical cancer without chemotherapy treatment would be eligible.\n* Previous exposure to chemotherapy treatment for another cancer or due to other medical condition (e.g. methotrexate exposure for treatment of rheumatoid arthritis).\n* Previous central nervous system (CNS) radiation, intrathecal therapy or CNS-involved surgery.\n* Participants with history of stroke, traumatic brain injury, brain surgery, Alzheimer's disease or other dementia.\n* Participants with active substance abuse and\u002For in treatment for substance abuse, or history of bipolar disorder, psychosis, schizophrenia, ADHD, or learning disability.\n* Participants who are enrolled in an active behavioral intervention (e.g., occupational therapy, physical therapy, etc.) or pharmaceutical intervention or who are in the follow-up phase of a cancer control trial or therapeutic trial that has extensive PRO follow-up after treatment ends. Participants who are enrolled in a therapeutic trial in which they have completed active treatment and require only minimal follow-up monitoring of toxicity and\u002For survival analysis (cancer-related mortality or all-cause mortality) would be eligible.\n* Hearing impairment unless adequately corrected with hearing aids to be able to hear over the phone for the neuropsychological testing.","100 Years",{"count":56,"type":21},386,[24],"This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.",[60,28],"Breast Cancer","RECRUITING","2026-04-22",{"date":64,"type":38},"2026-04-23",{"date":66,"type":38},"2024-02-29",{"date":68,"type":21},"2027-11-30",{"name":70,"class":45},"NRG Oncology",680,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":46},"100633882","the-role-of-potassium-channels-in-working-memory-impairments-of-chronic-cocaine-users-100633882","NCT07532460","The Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","Randomised, Double-Blind, Placebo-Controlled, Crossover Study Investigating the Role of Potassium Channels in Working Memory Impairments of Chronic Cocaine Users","POTCHICUD","Inclusion Criteria:\n\n* Current diagnosis of mild, moderate, or severe CoUD according to DSM-5\n* Minimum cocaine use of 1g\u002Fmonth in the last three months\n* Cocaine as the primary drug of consumption\n* Willingness to abstain from cocaine use at least 72 hours before prior to each study visit\n* Ability to read, understand and provide written informed consent\n* To be sufficiently fluent in German\n* Age between 20 and 50 years\n* Body mass index (BMI) between 19 and 30 kg\u002Fm2\n* If applicable: luteal phase of the menstrual cycle\n* For individuals with childbearing potential: use of contraceptive measures\n\nExclusion Criteria:\n\n* Presence or history of severe neurological disorders or head injuries\n* Current diagnosis of an acute or chronic infectious disease\n* If applicable: pregnancy and breastfeeding\n* Lifetime history of any epileptic seizures\n* Lifetime diagnosis of a cardiovascular disease, specifically arrhythmia and long QT syndrome\n* Clinically significant laboratory or ECG abnormality that could be a safety issue in the study\n* Lifetime diagnosis of liver or kidney disease including moderate or severe renal impairment (creatinine clearance \\\u003C 50 ml\u002Fmin)\n* Known hypersensitivity or allergy to 4-aminopyridine\n* Use of potassium channel blockers within the last 3 months\n* Use of psychotropic medication within the last 7 days\n* Use of inhibitors of the organic cation transporter 2 (OCT2), such as cimetidine\n* Lifetime diagnosis of schizophrenia, bipolar disorder, obsessive-compulsive disorder, or autism spectrum disorder according to DSM-5\n* Diagnosis of a current episode of depression\n* Current diagnosis of a moderate or severe substance use disorder other than CoUD according than DSM-5\n* Daily cannabis consumption in the past three months\n* (E-Cigarette) Fagerström Test of Nicotine Dependence Score \\> 5 (strong nicotine dependence)\n* Inability to follow the procedures of the study, e.g., due to language problems\n* Being related to or in any form dependent on the investigator\n* Prior participation (less than two years ago) in a study investigating working memory using the n-back task, the SWM, PAL, RVP, or LNST\n* Participation in another study with investigational drugs within the 30 days preceding and during the present study","20 Years",{"count":82,"type":21},40,[24],"The study aims to address the neurobiological basis of cognitive impairments in chronic cocaine users by investigating the potential impact of an acute potassium channel blockade on working memory performance and other cognitive functions.",[86,28],"Cocaine Use Disorder (CUD)",[31,88,89,90,91,92],"cocaine use disorder","potassium channels","working memory","4-aminopyridine","fampridine","2026-04-15",{"date":95,"type":38},"2026-04-20",{"date":97,"type":21},"2026-04",{"date":99,"type":21},"2027-08",{"name":101,"class":45},"Boris Quednow",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":122,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":46},"100617151","psychiatric-status-and-symptom-severity-in-graft-versus-host-disease-gvhd-100617151","NCT07314892","Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).","Prospective Assessment of the Impact of Psychiatric Status on Clinical Symptom Severity in Patients With Graft-versus-Host Disease (GvHD).","Psych-GvHD","Inclusion Criteria:\n\n* Adult patients with a clinically established diagnosis of graft-versus-host disease (GvHD) receiving specialist follow-up care at the Bone Marrow Transplantation Outpatient Clinic, University Clinical Center (UCK), Gdańsk.\n\nExclusion Criteria:\n\n* Severe psychiatric disorders precluding adequate cooperation, terminal-stage multiorgan failure, or refusal to provide informed consent for study participation.","75 Years",{"count":112,"type":21},200,"1 Year","OBSERVATIONAL","This prospective observational study evaluates the association between psychiatric status, GvHD-related symptom severity, and health-related quality of life in patients with graft-versus-host disease. Standardized and validated assessment tools, including the Lee Symptom Scale, will be used to collect psychiatric, clinical, and demographic data.",[117,118,119,120,121,28],"GVHD, Chronic","GVHD - Graft-Versus-Host Disease","GVHD","Quality of Life","Depression Disorders",[123,124,125,126],"GvHD","depression","quality of life","Cognitive impairment","2025-12-18",{"date":129,"type":38},"2026-01-02",{"date":131,"type":38},"2025-04-08",{"date":133,"type":21},"2028-10",{"name":135,"class":45},"Medical University of Gdansk"]